

Diagnósticos da América S.A.

Interim financial information

Six-month period ended

June 30, 2005 (Unaudited)

(A translation of the original interim financial information in Portuguese, prepared in accordance with accounting principles derived from the Brazilian Corporation Law and rules of the Brazilian Securities Commission - CVM)

Diagnósticos da América S.A.

Interim financial information (Unaudited)

Six-month period ended June 30, 2005

Contents

Management report	3 - 5
Independent accountants' review report	6
Balance sheets	7 - 8
Income statements	9
Notes to the interim financial information	10 - 44

Management report

Dear Shareholder,

The result for the quarter ended June 30, 2005 confirm the effort made to create value introduced by Diagnósticos da América, evidenced by the continual growth in gross operational income and the economies of scale and synergies in operations.

Gross operational income reached R\$ 144.1 million during the period, representing growth of 15.1% compared to the same period for the previous year. Image services reported the most significant growth of 30.4% in income, representing 38% of DASA's revenue. The greater number of units compared to the second quarter of 2004, and registration of new payers contributed to the increase of 11.1% in the volume of requests for examinations attended during 2Q/05. The Company's adjusted EBITDA reached R\$ 34.9 million during the period, representing growth of 19.6% compared to 2Q/04.

In terms of acquisitions, DASA made another important step in its strategy to expand on the diagnostic medicine market in Curitiba, Paraná, as a result of its purchase of Laboratório Frischmann Aisengart, a company that has a strong brand name that is widely recognized in the South of Brazil. Laboratório Frischmann has 16 patient attendance units, and reported revenue of R\$ 28.4 million and EBITDA of R\$ 3.2 million in 2004.

Including the operations of Laboratório Frischmann Aisengart, DASA now has an attendance network of 176 units and more than 5,000 employees, distributed between São Paulo, Rio de Janeiro, Curitiba and Brasília. For the quarter analyzed, a total of R\$ 500,000 was invested in training our staff, aimed to develop individuals who are committed to the Company's vision, mission, strategy and values.

Finally, on June 14, DASA was recognized, together with the main companies negotiated on the Bovespa, when it received an honorary mention in the category for Best Performance in Investor Relations from a first public offer. The IR Awards Brazil, promoted by the American magazine IR Magazine, reiterates DASA's commitment to the principles of corporate governance and transparency, which is incessantly follows.

Economic Scenario

During the second quarter of 2005, there was a change in the composition of macro economic bases for the Brazilian economy compared to the start of the year. Economic activity slowed down, affected by the continual increased in interest rates. Although the strong performance reported by the sectors aimed at exports, resulted in the balance of trade surplus, during the first semester of 2005, reaching a record US\$ 19.0 billion.

Despite the slow down in the price indices, the Central Bank of Brazil decided to reduce the economy's basic interest rate - SELIC, contrary to expectations of monetary control. The SELIC rate reached 19.75% at the end of June.

These movements have affected and may continue to affect the growth in economic activity during 2005.

Comments on Performance and Investments =

During the second quarter of 2005, Diagnósticos da América reported financial results consistent with its historic performance. Gross operational income reached R\$ 144.1 million during the period, representing an increase of 15.1% compared to the same quarter from the previous year. The EBITDA for 2Q/05 reported significant growth of 50.1%, compared to the same period from the previous year. Whilst the adjusted EBITDA reported growth of 19.6% compared to 2Q/04, reaching R\$ 34.9 million during the period. Furthermore, we recorded net profit of R\$ 5.0 million, reversing the loss of R\$ 8.0 million in 2Q/04.

Growth in gross operational income reflects the increase of 7.6% in income from clinical analyses and 30.4% in income from image services compared to the same quarter for 2004. This segment is particularly important for the Company, since it represents approximately 60% of the market for diagnostic medicine in Brazil - although it is only responsible for 38% of DASA's revenue. In addition, the investment in this group of services has favored the increase in average income per examination performed by the Company.

From an analysis of the gross income for each of the brand names that make up DASA's portfolio, we noted growth of 19.3% in the premium and executive segments and growth of 9.2% in the basic segment. Growth of more than 80% in gross operational income for Club DA was the highlight from the premium segment, whilst significant expansion in the services for the brand name Delboni Auriemo, related to its public recognition, levered growth in income for the executive segment. For the basic segment, registering new health plans and the constant search to increase volume should favor growth in income during the coming quarters.

Gross profit of R\$ 43.9 million reported during the second quarter for the year was 23.3% higher than that registered for the same period for 2004, motivated by economies of scale in the production of clinical analyses and synergies in operations involving image diagnostic services, as a result of centralizing the issuing of reports for some examinations. The increase in gross margin to 33.0%, 1,6 p.p. higher than the margin observed for 2Q/04 confirmed the gains in operational efficiency.

The following contributed to reversing the net loss for the period analyzed, a reduction of (1) R\$ 0.6 million in general and administrative expenses; (2) R\$ 4.4 million in financial expenses, resulting from the reduction in the net financial debt and increase in financial income; and (3) R\$ 3.6 million in amortization of goodwill, as a result of the end of the amortization period for purchases made in 1999.

Based on the results reported by DASA from April to June 2005, the profit per share reached R\$ 0.09.

During 2Q/05, a total of R\$ 14.6 million was invested in opening and reforming attendance units, including purchasing new image equipment. During this period, three new units were inaugurated, offering both clinical analyses and image services.

Finally, DASA agreed to the purchase of Laboratório Frischmann Aisengart in Curitiba, taking an important step in its expansion strategy in an important market in the South of Brazil. Besides enabling the Company to implement its segmentation strategy in the Curitiba market, this purchase represented DASA's presence in segments for environmental analyses, analyses of genetically modified organisms and toxicological analyses.

Information for shareholders

1. Performance on the Stock Exchange:

DASA's shares closed the second quarter of 2005 negotiated at R\$ 31.80 per share, representing a valuation of 18% during the period. At the same time, the Ibovespa index recorded a drop of 6% during the same period. A total of 5,814 negotiations were registered during the period, involving approximately R\$ 277.0 million in financial terms with all of the negotiations on the stock exchange.

2. Purchase of Laboratório Frischmann Aisengart:

On July 05, 2005, DASA purchased 92.92% of the shares in Laboratório Frischmann Aisengart, the leader in clinical analyses in the market in Curitiba (Paraná – South of Brazil). As a result of this purchase, Diagnósticos da América extended its activities in the city of Curitiba, an important region for consuming diagnostic medical services in Brazil. The transaction, approved by the Board of Directors on July 05, 2005, will be ratified by the shareholders in an EGM-Extraordinary General Meeting to be held on August 01, 2005.

3. Incorporation of Companies:

During the EGM to be held on August 01, 2005, the shareholders of DASA will decide on the proposal by the Company to incorporate the subsidiaries: Centro Radiológico da Lagoa Ltda., Presmedi Rio Serviços Médicos Ltda., Elkis e Furlanetto Centro de Diagnósticos e Análises Clínicas Ltda., Elkis e Furlanetto Laboratório Médico Ltda and Laboratório Pasteur de Patologia Clínica S/S Ltda.. As a result of this operation DASA will rationalize its activities within a unified structure, aimed to reduce costs and administrative expenses.

4. Approval of the Purchase of Laboratório Pasteur by CADE:

The Administrative Council for Economic Defense (CADE) approved the purchase of Laboratório Pasteur by Diagnósticos da América S.A., in accordance with the decision published on July 14, 2004, in the Federal Official Gazette. According to the report issued by this body, the decision by the Assembly was unanimous for fully approving the operation, with the exception of the restriction on the geographical limitation from the clause for not competing in the Federal District and the city of Formosa-GO, where Laboratório Pasteur undertakes activities.

Independent accountants' review report

To
The Board of Directors and Shareholders
Diagnósticos da América S.A.
Barueri - SP

We have reviewed the interim financial information of Diagnósticos da América S.A. and the consolidated interim financial information of Diagnósticos da América S.A. and its subsidiaries, for the six-month period ended June 30, 2005, which comprises the balance sheets, the statements of income, management report and other relevant information, prepared in accordance with the accounting practices adopted in Brazil.

Our review was prepared in accordance with the review standards established by IBRACON - Brazilian Institute of Independent Auditors and the Federal Accounting Council, and included, basically: (a) inquiry and discussion with management responsible for the accounting, financial and operating areas of the Company and its subsidiaries, regarding the main criteria adopted in the preparation of the quarterly information; and (b) review of the information and subsequent events, which have, or may have, a material effect on the financial situation and the operations of the Company and its subsidiaries.

Based on our special review, we are not aware of any material changes which should be made to the interim financial information above for it to be in accordance with accounting practices adopted in Brazil and regulations issued by the Brazilian Securities Commission (CVM), specifically applicable to the preparation of interim financial information.

July 22, 2005

KPMG Auditores Independentes
CRC 2SP014428/O-6

Adelino Dias Pinho
Accountant CRC 1SP097869/O-6

Diagnósticos da América S.A.

Balance sheets (Unaudited)

June 30, 2005 and March 31, 2005

(In thousands of Reais)

	<u>Parent Company</u>		<u>Consolidated</u>	
	<u>June 30, 2005</u>	<u>March 31, 2005</u>	<u>June 30, 2005</u>	<u>March 31, 2005</u>
Assets				
Current assets				
Cash and cash equivalents	3,467	3,834	3,793	4,046
Interest earning bank deposits	128,225	127,358	128,228	127,379
Trade accounts receivable	114,796	113,771	115,308	113,958
Inventories	13,290	14,282	13,290	14,282
Taxes recoverable	19,113	17,976	20,602	19,372
Prepaid expenses	1,260	1,883	1,268	1,883
Other receivables	6,334	5,320	9,085	9,155
	<u>286,485</u>	<u>284,424</u>	<u>291,574</u>	<u>290,075</u>
Noncurrent assets				
Interest earning bank deposits	9,614	8,031	9,614	8,031
Legal deposits	5,601	3,637	6,301	3,706
Related parties	19,319	14,605	-	-
Other receivable	-	1,327	-	1,327
	<u>34,534</u>	<u>27,600</u>	<u>15,915</u>	<u>13,064</u>
Permanent assets				
Investments	8,182	2,511	30,829	24,882
Property, plant and equipment	176,364	169,241	181,864	173,514
Deferred charges	36,284	39,825	36,288	39,828
	<u>220,830</u>	<u>211,577</u>	<u>248,981</u>	<u>238,224</u>
	<u><u>541,849</u></u>	<u><u>523,601</u></u>	<u><u>556,470</u></u>	<u><u>541,363</u></u>

See the accountants' review report and the accompanying notes to the interim financial information.

Diagnósticos da América S.A.

Balance sheets (Unaudited)

June 30, 2005 and March 31, 2005

(In thousands of Reais)

	<u>Parent Company</u>		<u>Consolidated</u>	
	<u>June 30, 2005</u>	<u>March 31, 2005</u>	<u>June 30, 2005</u>	<u>March 31, 2005</u>
Liabilities and shareholders' equity				
Current liabilities				
Suppliers	19,045	18,548	19,263	18,548
Loans and financing	42,353	30,591	43,094	32,413
Taxes and contributions payable	9,573	6,941	11,022	8,372
Salaries, social security charges and vacation payable	18,253	14,607	19,357	14,607
Installment taxes	1,955	1,912	6,477	7,206
Accounts payable from acquisition of subsidiaries	18,348	20,741	18,348	20,741
Unsecured liabilities in subsidiaries	6,870	4,934	-	-
Other accounts payable	15,233	11,964	18,133	15,777
	<u>131,630</u>	<u>110,238</u>	<u>135,694</u>	<u>117,664</u>
Long-term liabilities				
Loans and financing	87,780	100,514	88,162	100,514
Installment taxes	11,903	12,135	18,161	19,039
Accounts payable from acquisition of subsidiaries	18,208	18,094	18,208	18,094
Provision for contingencies	27,355	27,025	30,551	30,365
Processes with legal deposits	4,364	2,863	5,085	2,955
	<u>149,610</u>	<u>160,631</u>	<u>160,167</u>	<u>170,967</u>
Shareholders' equity				
Capital	216,136	216,136	216,136	216,136
Capital reserves	58,357	55,468	58,357	55,468
Accumulated losses	(13,884)	(18,872)	(13,884)	(18,872)
	<u>260,609</u>	<u>252,732</u>	<u>260,609</u>	<u>252,732</u>
	<u>541,849</u>	<u>523,601</u>	<u>556,470</u>	<u>541,363</u>

Diagnósticos da América S.A.

Income statements (Unaudited)

Six-month period ended June 30, 2005 and 2004

(In thousands of Reais, except for earnings per share)

	Three month period				Six month period			
	Parent Company		Consolidated		Parent Company		Consolidated	
	June 30, 2005	June 30, 2004	June 30, 2005	June 30, 2004	June 30, 2005	June 30, 2004	June 30, 2005	June 30, 2004
Gross services income	141.626	117.724	144.109	125.154	271.167	228.753	273.650	238.576
Deduction from gross income	(10.743)	(11.249)	(10.884)	(11.850)	(20.552)	(25.101)	(20.693)	(26.015)
Net income	130.883	106.475	133.225	113.304	250.615	203.652	252.957	212.561
Cost of services rendered	(89.070)	(75.854)	(89.323)	(77.695)	(171.683)	(145.362)	(171.935)	(148.483)
Gross profit	41.813	30.621	43.902	35.609	78.932	58.290	81.021	64.078
Operational income (expenses)								
Administrative and general	(22.231)	(17.415)	(24.346)	(23.137)	(37.906)	(28.739)	(40.363)	(35.280)
Financial income (expenses), net	(2.493)	(6.523)	(3.089)	(7.460)	(5.834)	(12.472)	(7.750)	(13.572)
Equity in subsidiaries	(749)	(621)	-	-	(2.235)	(1.128)	-	-
Amortization of goodwill	(8.095)	(11.691)	(8.094)	(11.691)	(15.845)	(22.914)	(15.845)	(22.914)
Other operational income	(513)	(493)	(514)	(661)	(571)	2.161	(400)	1.993
	(34.081)	(36.743)	(36.043)	(42.949)	(62.391)	(63.092)	(64.358)	(69.773)
Operational income	7.732	(6.122)	7.859	(7.340)	16.541	(4.802)	16.663	(5.695)
Nonoperational result	(73)	(570)	(167)	648	(289)	(587)	(376)	306
Net income for the period before taxes	7.659	(6.692)	7.692	(6.692)	16.252	(5.389)	16.287	(5.389)
Income tax and social contribution	(2.671)	(1.262)	(2.704)	(1.262)	(5.682)	(2.138)	(5.717)	(2.138)
Net income for the period	4.988	(7.954)	4.988	(7.954)	10.570	(7.527)	10.570	(7.527)
Earnings per share - R\$	0,09	(1,68)	0,09	(1,68)	0,20	(1,59)	0,20	(1,59)
Number of shares	53.607.935	4.730.112	53.607.935	4.730.112	53.607.935	4.730.112	53.607.935	4.730.112

See the accountants' review report and the accompanying notes to the interim financial information.

1 Operations

The Company provides health assistance services to company employees covered by health insurance plans, insurance companies, medical-hospital assistance companies, other corporate entities and individuals in the following areas: (i) clinical analysis, directly, or as a supplementary nature, through the intermediary of contracted laboratories; and (ii) diagnostic medicine, exclusively through third parties and specialized clinics, in the following areas, as well as others that medical development determines in the future: a) clinical pathology; b) cytology and pathological anatomy; c) diagnosis by images and graphic methods; d) immunization, rehabilitation and ophthalmology; e) nuclear medicine and f) clinical trials. The company can also invest in others companies, business or non-business, as a partner, quotaholder or shareholder. The Company closed period with 160 operational units (148 in 2004), as it follows:

Brands	Locality	June 30,	
		2005	2004
Delboni Auriemo	São Paulo	30	29
Lavoisier	São Paulo	49	52
Bronstein	Rio de Janeiro	37	39
Lâmina	Rio de Janeiro	18	17
Santa Casa	Curitiba	8	10
Delboni Paraná	Curitiba	6	1
Pasteur	Brasília	<u>12</u>	<u>-</u>
		<u>160</u>	<u>148</u>

At June 30, 2005 Club DA had 10 units annexed to Delboni Auriemo and 2 units annexed to Lâmina.

2 Preparation and presentation of the interim financial information

The interim financial information was prepared in accordance with Brazilian Corporation Law and the rules of the Brazilian Securities Commission - CVM, which are consistent with those applied at December 31, 2004.

Summary of the principal accounting practices

a. Income statement

Income and expenses are recognized on the accrual basis. Revenue from services rendered is recognized in the income statement in function of its realization.

b. Accounting estimates

The accounting estimates were established considering objective and subjective factors, based on management's opinion of the appropriate amount to be recorded in the quarterly information. Significant items subject to these estimates and assumptions include estimated time periods for recovery and consequent amortization of the goodwill originating from the acquisition of investments and other deferred expenses, provision for doubtful accounts, provision for inventories, provision for contingencies and valuation of derivative instruments. The settlement of transactions involving these estimates may result in different amounts due to the lack of precision inherent to the process for determining such. The Company reviews the estimates and assumptions quarterly.

c. Foreign currency

Monetary assets and liabilities denominated in foreign currencies were translated into Reais at the foreign exchange rate prevailing at the balance sheet date. Foreign exchange differences arising on translation are recognized to the income statement.

d. Current and noncurrent assets

- **Cash and cash equivalents**

Cash and cash equivalents comprise cash balances and bank deposits.

- **Interest earning bank deposits**

Interest earning bank deposits are recorded at cost plus income accrued up to the balance sheet date.

- **Provision for doubtful accounts**

The provision for doubtful accounts has been recorded at amounts considered sufficient by the management to cover eventual losses from the realization of credits.

- **Inventories**

Inventories are stated at the lower of weighted average cost or market value. Inventories are used for clinical analysis exams and imaging.

- **Other current and noncurrent assets**

Other current and noncurrent assets are presented at the net realization value.

e. Permanent assets

- **Investments**

Investments in subsidiary companies are valued using the equity method. The goodwill is based on future profitability from operations undertaken by the target company, with profitability forecasts prepared by management projected for 5 years.

- **Property, plant and equipment**

Stated at acquisition cost and/or construction. Depreciation is calculated using the straight-line method at the rates described in Note 10 and takes into consideration the estimated useful life of the assets. Leasehold improvements are amortized over the lower of the remaining lease term or the useful life of the improvement.

- **Deferred charges**

Deferred charges are related to expenses for expansion of the patient service centers and are amortized using the straight-line method over a period between 5 and 10 years. The goodwill calculated from the mergers of investments is based on the future profitability of operations undertaken by these companies, according to profitability forecasts prepared by management projected over 5 years.

f. Current and noncurrent liabilities

Stated at the amounts acknowledged or estimated, plus, when applicable, the corresponding charges, and monetary and exchange variations incurred up to the balance sheet date.

g. Goodwill from the merger of the parent company

The goodwill recorded previously by the controlling company was classified after the merger against the capital reserve account in shareholders' equity of the Company that resulted from the merger. Later, the amortization of goodwill, for a maximum of five years, has been credited to this capital reserve account, with the corresponding entry recorded to income for the quarter. This procedure was supported by tax legislation, article 11 of Law 9718 of November 27, 1998, since the Brazilian Corporation Law does not deal with this matter.

h. Current and deferred income tax and social contribution

Current income tax and social contribution are calculated based on the effective rates of income tax and social contribution on net profit and take into account the compensation of tax losses and the negative basis for social contribution, limited to 30% of taxable income.

The Company has tax losses carryforwards negative basis of social contribution and temporary differences. Management decision regarding the non recognition of the deferred tax assets effects resulting from the aforementioned fiscal benefits is in accordance with CVM Instruction 371 of June 27, 2002, and considered the non existence of profits being reported in recent years.

3 Consolidated financial information

The consolidated quarterly information includes the direct subsidiaries, listed below:

	June 30, 2005	March 31, 2005
Centro Radiológico da Lagoa Ltda.	99,99%	99,99%
Presmedi Rio Serviços Médicos Ltda.	99,99%	99,99%
Elkis e Furlanetto Centro de Diagnósticos e Análises Clínicas Ltda.	100%	100%
Elkis e Furlanetto Laboratório Médico Ltda.	100%	100%
L.A.C. Laboratório de Análises Clínicas S/C Ltda.	-	100%
Laboratório Pasteur Patologia Clínica S/S Ltda.	100%	-

The accounting policies were applied of uniform form in the companies consolidated.

The process for consolidating the assets and liabilities and the profit and loss account is by totaling the balances in the asset and liability accounts and the expense accounts according to their nature, with the following eliminations:

- Investment interests in the capital, reserves and accumulated results;
- Inter-company asset and liability balances and the results between consolidated companies.

4 Interest earnings bank deposits

	<u>Parent Company</u>		<u>Consolidated</u>	
	June 30, 2005	March 31, 2005	June 30, 2005	March 31, 2005
Interest earnings bank deposits	137,839	135,389	137,842	135,410
Amount classified in current assets	<u>(128,225)</u>	<u>(127,358)</u>	<u>(128,228)</u>	<u>(127,379)</u>
Noncurrent assets				
Restrict deposits	<u>9,614</u>	<u>8,031</u>	<u>9,614</u>	<u>8,031</u>

The interest earnings bank deposit classified to current assets refer to variable income funds, earning an average rate of 100% as of June 30, 2005 (100,5 % as of March 31, 2005) of the Interbank Deposit Certificate (CDI). The objective of the funds in which the Company invests, is to provide the shareholders with profitability by investing their funds in investment fund quotas, whose investment policy includes the possibility of concentrating investments in public and private securities.

The long term bank deposits remunerated at an average rate of 79.9% of the CDI guarantee payment of liabilities assumed with the previous shareholders Laboratório Bronstein S.A., Bronstein Administradora Laboratorial S.A., Elkis e Furlanetto- Centro de Diagnósticos e Análises Clínicas Ltda., Elkis e Furlanetto - Laboratório Médico Ltda. e L.A.C. -Laboratório de Análises Clínicas S/C Ltda., from the purchase of all of the shares or quotas in these companies.

5 Trade accounts receivable

	Parent Company		Consolidated	
	June 30, 2005	March 31, 2005	June 30, 2005	March 31, 2005
Current:				
Trade notes receivable	137,644	134,524	138,156	135,510
Checks in collection	1,405	2,391	1,405	2,391
Credit cards	1,145	897	1,145	897
Returned checks	<u>2,009</u>	<u>1,985</u>	<u>2,009</u>	<u>1,985</u>
	142,203	139,797	142,715	140,783
Less:				
Provision for doubtful accounts	(25,398)	(24,041)	(25,398)	(24,840)
Provision for losses from returned checks	<u>(2,009)</u>	<u>(1,985)</u>	<u>(2,009)</u>	<u>(1,985)</u>
	<u>114,796</u>	<u>113,771</u>	<u>115,308</u>	<u>113,958</u>

6 Inventories

	Parent Company		Consolidated	
	June 30, 2005	March 31, 2005	June 30, 2005	March 31, 2005
Inventories:				
Domestic direct material	3,974	3,903	3,974	3,903
Imported direct material	5,110	6,135	5,110	6,135
Domestic secondary material	2,172	2,070	2,172	2,070
Consumption material	2,227	2,349	2,227	2,349
Inventories held by third parties	202	313	202	313
Provision for obsolescence	<u>(395)</u>	<u>(488)</u>	<u>(395)</u>	<u>(488)</u>
	<u>13,290</u>	<u>14,282</u>	<u>13,290</u>	<u>14,282</u>

7 Taxes recoverable

	<u>Parent Company</u>		<u>Consolidated</u>	
	June 30, 2005	March 31, 2005	June 30, 2005	March 31, 2005
Income tax recoverable	5,783	6,770	5,966	6,934
Social contribution recoverable	6,655	5,651	6,914	5,854
COFINS and PIS tax withheld	5,210	4,338	5,649	4,764
Others	<u>1,465</u>	<u>1,217</u>	<u>2,073</u>	<u>1,820</u>
	<u>19,113</u>	<u>17,976</u>	<u>20,602</u>	<u>19,372</u>

8 Related parties

	<u>Parent Company</u>	
	June 30, 2005	March 31, 2005
Subsidiary companies		
Centro Radiológico da Lagoa Ltda. Current accounts (a)	7,931	6,534
Presmedi Rio Serviços Médicos Ltda. Current accounts	147	93
Elkis e Furlanetto Centro de Diagnósticos e Análises Clínicas Ltda. Current accounts (b) Advanced for future capital increase (c)	4,710 4,879	2,428 4,879
Elkis e Furlanetto Laboratório Médico Ltda. Current accounts Advanced for future capital increase	312 440	231 440
Laboratório Pasteur Patologia Clínica S/S Ltda. Advanced for future capital increase	<u>900</u>	<u>-</u>
	<u>19,319</u>	<u>14,605</u>

The most significant balances involving related parties are presented below:

- **Centro Radiológico da Lagoa Ltda. - CRL**

- a. Current accounts with related parties

Refers mainly to the Company assuming the financing of its CRL subsidiary. There is no due date for the amount receivable and no financial interests are charged.

- **Elkis e Furlanetto Centro de Diagnósticos e Análises Clínicas Ltda.**

- b. Current accounts

The Company has assumed the liabilities of its subsidiary for payment of taxes and obligations. There is no due date for the amount receivable and no financial interests are charged.

- c. Advance for future capital increase

The Company granted its subsidiary, Elkis e Furlanetto C.D.A.C. Ltda. advances for future capital increases, and during the Board of Directors' meeting held on July 01, 2004, an increase in the subsidiary's capital was authorized, not yet paid in, of R\$ 4,879.

The amounts involving other operations with related parties have been summarized below, with the more significant amounts presented as follows:

	<u>June 30,2005</u>		<u>June 30,2004</u>	
	Expenses	Permanent assets	Expenses	Permanent assets
Related parties				
Terra Molhada Participações Ltda. (a)	1,620	-	3,622	-
Leandra Schwam Auriemo EPP	357	-	621	-
Parkbem Multiserviços S/C Ltda. (b)	2,952	27	2,863	1
Patrimônio Investimentos e Participações Ltda. (c)	1,259	-	740	-
RMA Construtora Ltda. (d)	833	1,600	353	2,093
Touch Tecnologia e Informática Ltda	-	992	-	690
	<u>7,021</u>	<u>2,619</u>	<u>8,199</u>	<u>2,784</u>

a. Terra Molhada Participações Ltda.

The Company rented three properties (central laboratory and the service units located on Avenida Brasil and Rua Baluarte, in São Paulo) from Terra Molhada Participações Ltda., a Company controlled by Dr. Caio Roberto Chimenti Auriemo, the managing director and President of the Company's Board of Directors and the controlling shareholder of Balu 460 Participações S.A., which controls DASA Participações S.A., the Company's Parent Company. The rental contracts for the three properties were renewed in May 2004 for an additional period of 10 years. With regard to these rentals, R\$ 1,620 was paid during the six-month period ended June 30, 2005 (R\$ 3,622 in the six-months ended June 30, 2004).

b. Parkbem Multiserviços S/C Ltda.

This company, controlled by José Auriemo Neto, nephew of Dr. Caio Auriemo, supplies cleaning, security and parking services to the service units. With regard to these services, a total of R\$ 2,979 was paid in the 6 month period ended June 30, 2005 (R\$ 2,864 to June 30, 2004).

c. Patrimônio Investimentos e Participações Ltda.

This company is related to Pátria – Banco de Negócios Assessoria, Gestão e Participação Ltda., the manager of certain funds, and indirect shareholders of the Company, and provides financial consulting services to advise the company on mergers and acquisitions. During the semester ended June 30, 2005, a total of R\$ 1,259 was spent (R\$ 740 at June 30, 2004).

d. RMA Construtora Ltda.

This construction company owned by Renato Magnanini Auriemo, son of Dr. Caio Auriemo, supplies civil engineering services for the construction and refurbishment of the service units. With regard to these services, a total of R\$ 2,433 was paid in the 6 month period ended June 30, 2005 (R\$ 2,446 to June 30, 2004).

9 Investments

	Parent Company		Consolidated	
	June 30, 2005	March 31,2005	June 30, 2005	March 31, 2005
Investments in subsidiary companies:				
Centro Radiológico da Lagoa Ltda.	(6,341)	(6,805)	-	-
Elkis e Furlanetto C.D.A.C. Ltda.	(16,359)	(17,415)	-	-
Elkis e Furlanetto LM Ltda.	1,824	1,868	-	-
Laboratório Pasteur Patologia Clínica S/S Ltda.	(1,752)	-	-	-
Goodwill on the purchase of subsidiaries:				
Centro Radiológico da Lagoa Ltda.	9,280	9,280	9,280	9,280
Elkis e Furlanetto C.D.A.C. Ltda.	21,130	21,130	21,130	21,130
Elkis e Furlanetto LM Ltda.	777	777	777	777
Laboratório Pasteur Patologia Clínica S/S Ltda.	7,883	-	7,883	-
Accumulated amortization:				
Centro Radiológico da Lagoa Ltda.	(2,938)	(2,475)	(2,938)	(2,475)
Elkis e Furlanetto C.D.A.C. Ltda.	(4,771)	(3,715)	(4,771)	(3,715)
Elkis e Furlanetto LM Ltda.	(176)	(136)	(176)	(136)
Laboratório Pasteur Patologia Clínica S/S Ltda.	(377)	-	(377)	-
Work of art	2	2	2	2
Investment in gold	-	-	19	19
	<u>8,182</u>	<u>2,511</u>	<u>30,829</u>	<u>24,882</u>

The main information on the investments in the shareholders' equity of these investments is as follows:

	CRL	Presmedi	Elkis CDAC	Elkis LM	Pasteur	Total
Capital quotas	2,825,038	222,814	4,600,000	900,000	1,900,000	
Number of quotas held	2,825,036	222,812	4,600,000	900,000	1,900,000	
Investment interest	99.99%	99.99%	100.00%	100.00%	100.00%	
Shareholders' equity at June 30, 2005	(7,956)	(1,128)	(20,485)	1,824	(1,752)	
Income (loss) in the investment for the period	(<u>246</u>)	(<u>27</u>)	(<u>563</u>)	(<u>44</u>)	<u>131</u>	
Balances for investments in subsidiaries classified as investments at June 30, 2005	(<u>6,341</u>)	<u>-</u>	(<u>16,359</u>)	<u>1,824</u>	(<u>1,752</u>)	(<u>22,628</u>)
Balances for investments in subsidiaries classified to current liabilities (unsecured liabilities) at June 30, 2005	(<u>1,615</u>)	(<u>1,128</u>)	(<u>4,127</u>)	<u>-</u>	<u>-</u>	(<u>6,870</u>)
Equity in income of subsidiaries	(<u>246</u>)	(<u>27</u>)	(<u>563</u>)	(<u>44</u>)	<u>131</u>	(<u>749</u>)

The unsecured liabilities for the companies Centro Radiológico da Lagoa Ltda., Presmedi Rio Serviços Médicos Ltda., Elkis e Furlanetto Centro de Diagnósticos e Análises Clínicas Ltda. for the amounts of R\$ 1,615, R\$ 1,128, R\$ 4,126, respectively, which amount to R\$ 6,869 (R\$ 4,934 at March 31, 2005) are classified in the Company's balance sheet as unsecured liabilities in subsidiaries.

The main movements on the investment accounts for the quarter are presented below:

	CRL	Presmedi	Elkis CDAC	Elkis LM	Elkis LAC	Pasteur	Total
Balance for investments at March 31, 2005	(7,710)	(1,101)	(19,923)	1,868	(420)	-	(27,286)
Acquisition during the quarter	-	-	-	-	-	(1,883)	(1,883)
Company closed down during the quarter	-	-	-	-	420	-	420
Equity in income of subsidiaries	(246)	(27)	(563)	(44)	-	131	(749)
Balance for investments at June 30, 2005	<u>(7,956)</u>	<u>(1,128)</u>	<u>(20,486)</u>	<u>1,824</u>	<u>-</u>	<u>(1,752)</u>	<u>(29,498)</u>
Classified in the Company's balance sheet as:							
Investments	(6,341)	-	(16,359)	1,824	-	(1,752)	(22,628)
Unsecured liabilities	(1,615)	(1,128)	(4,127)	-	-	-	(6,870)
	<u>(7,956)</u>	<u>(1,128)</u>	<u>(20,486)</u>	<u>1,824</u>	<u>-</u>	<u>(1,752)</u>	<u>(27,498)</u>

Purchases and investments during the quarter - Pasteur - On April 04, 2005, the Company agreed to the purchase of all of the capital in Laboratório Pasteur Patologia Clínica S/S Ltda., located in Brasília - DF, which has 12 small clinical analysis units, for the sum of R\$ 6,000, with this purchase price including goodwill of R\$ 7,883. This operation was considered by the Administrative Council for Economic Defense of Economic - CADE, which published a favorable report in the Federal Official Gazette on July 14, 2005.

Winding up of subsidiary during the quarter - LAC - In accordance with the private instrument for corporate dissolution, the Company decided to dissolve the company L.A.C. - Laboratório de Análises Clínicas Ltda.

10 Property, plant and equipment

	Parent Company				
	Depreciation Rate % p.a.	June 30, 2005			March 31, 2005
		Cost	Depreciation	Net	Net
Leasehold improvements	12	107,233	(44,635)	62,598	63,216
Machinery and equipment	10	116,047	(44,058)	71,989	69,809
Furniture and fixtures	10	16,393	(6,084)	10,309	10,203
Facilities	10	1,827	(1,124)	703	731
Hardware and software	20	32,206	(15,802)	16,404	14,606
Vehicles	20	142	(72)	70	77
Library	10	56	(27)	29	30
Other fixed assets		88	-	88	88
Constructions in process (a)		<u>14,174</u>	<u>-</u>	<u>14,174</u>	<u>10,481</u>
		<u>288,166</u>	<u>(111,802)</u>	<u>176,364</u>	<u>169,241</u>

	Consolidated				
	Depreciation Rate % p.a.	June 30, 2005			March 31, 2005
		Cost	Depreciation	Net	Net
Properties	4	867	(240)	627	-
Leasehold improvements	12	110,426	(47,096)	63,330	64,048
Machinery and equipment	10	123,929	(49,381)	74,548	72,240
Furniture and fixtures	10	17,680	(6,993)	10,687	10,430
Facilities	10	2,987	(1,937)	1,050	1,092
Hardware and software	20	33,909	(16,832)	17,077	14,875
Vehicles	20	277	(166)	111	86
Library	10	71	(41)	30	32
Other fixed assets		88	-	88	88
Constructions in process (a)		<u>14,316</u>	<u>-</u>	<u>14,316</u>	<u>10,623</u>
		<u>304,550</u>	<u>(122,686)</u>	<u>181,864</u>	<u>173,514</u>

- (a) The construction in progress includes ICMS (VAT) on imports recognized by the Company, amounting to R\$ 6,517 at June 30, 2005 in the parent company and on consolidation (R\$ 6,439 at March 31, 2005) with the corresponding entry made to the provision for contingencies, classified at non current liabilities. This refers to the ICMS on the import of equipment that was not paid since the Company has legally questioned this payment. For further information on ICMS on imports see Note 18.

11 Deferred charges

		<u>Parent company</u>				
	End of amortization	Amortization rate % p.a.	<u>June 30, 2005</u>			<u>March 31, 2005</u>
			Cost	Amortization	Net	Net
Pre-operating expenses			41,896	(12,940)	28,956	29,228
Goodwill on merger of subsidiary:						
Atacama S.A.	Dec-05	20	55,967	(50,078)	5,889	9,019
Laboratório de Patologia Clínica Curitiba S/C	Jan-08	20	2,785	(1,346)	1,439	1,578
			<u>100,648</u>	<u>(64,364)</u>	<u>36,284</u>	<u>39,825</u>
		<u>Consolidated</u>				
	End of amortization	Amortization rate % p.a.	<u>June 30, 2005</u>			<u>March 31, 2005</u>
			Cost	Amortization	Net	Net
Pre-operating expenses			41,903	(12,943)	28,960	29,231
Goodwill on merger of subsidiary:						
Atacama S.A.	Dec-05	20	55,967	(50,078)	5,889	9,019
Laboratório de Patologia Clínica Curitiba S/C	Jan-08	20	2,785	(1,346)	1,439	1,578
			<u>100,655</u>	<u>(64,367)</u>	<u>36,288</u>	<u>39,828</u>

12 Suppliers

	<u>Parent Company</u>		<u>Consolidated</u>	
	<u>June 30, 2005</u>	<u>March 31, 2005</u>	<u>June 30, 2005</u>	<u>March 31, 2005</u>
Domestic suppliers	15,833	15,247	16,051	15,247
Foreign suppliers	<u>3,212</u>	<u>3,301</u>	<u>3,212</u>	<u>3,301</u>
	<u>19,045</u>	<u>18,548</u>	<u>19,263</u>	<u>18,548</u>

The balance for foreign suppliers of US\$ 1,367 (US\$ 1,238 at March 31, 2005) refers to the purchase of imported materials used in clinical exams.

13 Loans and financing

	<u>Parent Company</u>		<u>Consolidated</u>	
	June 30, 2005	March 31, 2005	June 30, 2005	March 31, 2005
Local currency:				
Loans guaranteed accounts (a)	3,861	1,379	4,378	3,201
Bank loans (b)	45,177	44,973	45,783	44,973
Foreign currency				
Bank loans (c)	26,496	29,812	26,496	29,812
Equipment suppliers (d)	52,249	54,941	52,249	54,941
Leasing of equipment	<u>2,350</u>	<u>-</u>	<u>2,350</u>	<u>-</u>
	<u>130,133</u>	<u>131,105</u>	<u>131,256</u>	<u>132,927</u>
Short term installments to amortize classified as current liabilities	(<u>42,353</u>)	(<u>30,591</u>)	(<u>43,094</u>)	(<u>32,413</u>)
Long-term liabilities	<u>87,780</u>	<u>100,514</u>	<u>88,162</u>	<u>100,514</u>

a. Loans guaranteed accounts

The financings in local currency refer to guaranteed current accounts, with interest varying between 107.0% and 111.0% of CDI. The resources are used for maintaining the Company's cash flow.

b. Bank loans - Local currency

Contracted from financial institutions and bearing interest of 110% to 111,6% of CDI. These loans are guaranteed by the indirect controlling shareholders Platypus S.A. and Balu 460 Participações S.A.

c. Bank loans - Foreign currency (US\$ 000)

Contracted from local financial institutions, and report the amount payment of US\$ 7,166 (US\$ 8,293 at March 31, 2005), bearing interest of 13.06% p.a. on US\$ 5,750 and 5.21% p.a. on US\$ 1,416. Swap operations were contracted to protect against foreign exchange variations for the same amounts and same maturity terms for the loan repayments. These loans are guaranteed by the indirect controlling shareholders Plyatipus S.A. and Balu 460 Participações S.A.

d. Suppliers of equipment - Foreign currency (US\$ 000)

The balance for suppliers of equipment was US\$ 15,776 (US\$ 16,581 at March 31, 2004), arising from the import of machines and equipments. The interest due is calculated at a rate between 7.5% and 8.5% p.a.

In order to avoid exposure to foreign exchange rates, the Company contracted derivative instruments, “swap”, with the bank Votorantim S.A., amounting to R\$ 34,110, and the contracts will be settled by December 2010. At June 30, 2005, these derivative instruments resulted in a loss of R\$ 15,169 (R\$ 10,734 at March 31, 2005). These loans are guaranteed by the indirect Parent Companies Platypus S.A. and Balu 460 Participações S.A.

The bank loans and borrowings classified as non current liabilities are due as follows:

Maturity date	Parent Company	Consolidated
2006	18,337	18,442
2007	20,444	20,631
2008	18,322	18,412
2009	12,220	12,220
2010	1,513	1,513
2011	882	882
2012	<u>221</u>	<u>221</u>
	71,939	72,321
Swap	<u>15,841</u>	<u>15,841</u>
	<u>87,780</u>	<u>88,162</u>

14 Salaries, social security charges and vacation payable

	Parent Company		Consolidated	
	June 30, 2005	March 31, 2005	June 30, 2005	March 31, 2005
Salaries payable	2,684	2,240	2,808	2,240
Social security charges	2,545	2,312	2,852	2,312
Provision for vacation, and social security charges	12,472	9,575	13,141	9,575
Others	<u>552</u>	<u>480</u>	<u>556</u>	<u>480</u>
	<u>18,253</u>	<u>14,607</u>	<u>19,357</u>	<u>14,607</u>

15 Installment taxes

	Maturity Date	Parent Company		Consolidated	
		June 30, 2005	March 31, 2005	June 30, 2005	March 31, 2005
Installment taxes - REFIS municipal (a)	2010	4,934	5,033	4,934	5,033
Installment taxes - PAES program (b)	2013	8,924	9,014	8,924	9,014
Centro Radiológico da Lagoa Ltda.:					
- COFINS	2008	-	-	650	1,317
- INSS	2009	-	-	1,317	1,418
- PIS	2008	-	-	216	443
Elkis e Furlanetto C.D.A.C. Ltda. :					
- INSS	2008	-	-	3,524	3,863
- COFINS	2010	-	-	1,417	1,423
- ISS	2006	-	-	891	1,096
Elkis e Furlanetto L.M. Ltda. :					
- INSS	2009	-	-	1,125	1,163
Presmedi Rio Serviços Médicos Ltda. :					
- INSS	2009	-	-	523	542
Lab. Pasteur Patologia Clínica S/S Ltda.:					
- INSS	2006	-	-	294	-
Others		<u>-</u>	<u>-</u>	<u>823</u>	<u>933</u>
		<u>13,858</u>	<u>14,047</u>	<u>24,638</u>	<u>26,245</u>
Installments due in the short term classified as current liabilities		<u>(1,955)</u>	<u>(1,912)</u>	<u>(6,477)</u>	<u>(7,206)</u>
Noncurrent liabilities		<u>11,903</u>	<u>12,135</u>	<u>18,161</u>	<u>19,039</u>

- a. Taxes payable by the Company in installments under the municipal Tax Recovery Program (REFIS) (Municipal law nº 13.092 of December 7, 2000) totaling R\$ 4,934 as of June 30, 2005 (R\$ 5,033 as of March 31, 2005), refer to taxes due to the municipality of São Paulo. The tax debt was divided into 120 monthly installments, indexed by the long-term interest rate (TJLP) and the installments extend until December 2010.
- b. On July 29, 2003, the Company adhered to the PAES program (Law 10,684), declaring tax debts related to PIS and COFINS (programs of the federal government for social integration) which were being discussed judicially. On June 30, 2005 the total of installments was R\$ 8,924 (R\$ 9,014 at March 31, 2005), which is divided into 120 monthly installments and updated by the TJLP. Payment of these installments extends to June 2013.

16 Accounts payable from acquisition of subsidiaries

	<u>Parent Company</u>		<u>Consolidated</u>	
	<u>June 30, 2005</u>	<u>March 31, 2005</u>	<u>June 30, 2005</u>	<u>March 31, 2005</u>
(a) Previous owners Bio-Ciência Lavoisier Análises Clínicas S/C Ltda.	13,970	13,611	13,970	13,611
(b) Previous owners Laboratório Bronstein S.A.	5,781	5,614	5,781	5,614
(c) Previous owners Lâmina - Laboratório de Análises Médicas e Investigações Anátomo-Patológicas S.A.	6,647	11,049	6,647	11,049
(d) Previous owners Laboratório de Patologia C. Curitiba S/C Ltda.	405	404	405	404
(e) Previous owners Centro Radiológico da Lagoa e Presmedi Rio Serviços Médicos Ltda.	330	756	330	756
(f) Previous owners Elkis e Furlanetto C.D.A.C. Ltda.	7,162	7,401	7,162	7,401
(g) Previous owners Pasteur Patologia Clínica S/S Ltda.				
	<u>2,261</u>	<u>-</u>	<u>2,261</u>	<u>-</u>
	<u>36,556</u>	<u>38,835</u>	<u>36,556</u>	<u>38,835</u>
Installments due in the short term classified as current liabilities	<u>(18,348)</u>	<u>(20,741)</u>	<u>(18,348)</u>	<u>(20,741)</u>
Noncurrent liabilities	<u>18,208</u>	<u>18,094</u>	<u>18,208</u>	<u>18,094</u>

The accounts payable from the purchase of subsidiaries refer to amounts due to the previous owners as a result of the purchase of 100% of the capital in these companies. The debts are corrected and are due as follows:

- a. Bio-Ciência Lavoisier Análises Clínicas S.A. - Monetary corrected by the variation in the IGP-M, plus interest of 10% p.a. The debt amortizations will be made until October 2005.

- b. Laboratório Bronstein S.A. e Bronstein Administradora Laboratorial S.A. - Corrected using the same rates as those for the funds invested in investment funds, managed by financial institutions, as reported in note 4, and will be settled in December 2006.
- c. Lâmina - Laboratório de Análises Médicas e Investigações Anátomo-Patológicas S.A. - Monetary corrected by the variation in the IGP-M, plus interest of 12% p.a. The debt amortizations will be made until March 2007.
- d. Laboratório de Patologia Clínica Curitiba S/C - Refers to tax credits which have to be transferred to the previous partners when the Company takes the benefit from such.
- e. Centro Radiológico da Lagoa Ltda. e Presmedi Rio Serviços Médicos Ltda. - Monetary corrected by the variation in the IGP-M. The debt amortizations will be made until November 2005.
- f. Elkis e Furlanetto - Centro de Diagnósticos e Análises Clínicas Ltda., Elkis e Furlanetto - Laboratório Médico Ltda. e L.A.C. - Laboratório de Análises Clínicas S/C Ltda. - Part of this debt, R\$ 4,144, is being corrected using the same rates as those for the funds invested in investment funds, managed by a financial institution, as reported in note 4, and R\$ 2,708 is being monetary corrected by the variation in the IGP-M. The debt amortizations will be made until May 2011.
- g. Laboratório Pasteur Patologia Clínica S/S Ltda. - Monetary corrected by the variation in the IPCA. The debt amortizations will be made until May 2007.

17 Other accounts payable

	<u>Parent Company</u>		<u>Consolidated</u>	
	June 30, 2005	March 31, 2005	June 30, 2005	March 31, 2005
Rentals payable	1,896	1,706	1,896	1,706
Third-party services	2,502	2,853	2,502	2,853
Provisions for freelance professionals	5,288	3,937	5,288	3,937
Franchisee commission payable	893	1,115	893	1,115
Account receivable from previous owners	-	-	2,729	3,813
Other accounts payable	<u>4,654</u>	<u>2,353</u>	<u>4,825</u>	<u>2,353</u>
	<u>15,233</u>	<u>11,964</u>	<u>18,133</u>	<u>15,777</u>

18 Provision for contingencies

	<u>Parent Company</u>		<u>Consolidated</u>	
	June 30, 2005	March 31, 2005	June 30, 2005	March 31, 2005
ICMS on imports (a)	21,967	20,266	21,967	20,266
INSS - processes 1993 to 1999	370	1,847	370	1,847
Provision for labor contingencies (b)	2,599	2,559	2,798	2,718
Provision for civil contingencies (c)	1,799	1,755	1,803	1,759
Provision for tax contingencies (d)	<u>620</u>	<u>598</u>	<u>3,613</u>	<u>3,775</u>
	<u>27,355</u>	<u>27,025</u>	<u>30,551</u>	<u>30,365</u>

a. ICMS on imports

The Company, based on the opinion of its legal advisors, has not paid ICMS on the import of goods and equipment since February 2000, since it is not a taxpayer for this tax, thus preventing it from being compensated, and thus not observed the principle of non accumulation.

For ICMS taxes on imports after the publication of Constitutional Amendment 33/01, the Company's external legal counsel believes that the chances of loss are possible. At June 30, 2005 there was only one administrative proceeding for approximately R\$ 3,500. However, there is one administrative proceeding filed against the customs agent that may have direct consequences on all the imports that the Company made through him. The total amount is approximately R\$ 21,967 at June 30, 2005 (R\$ 20,266 at March 31, 2005).

b. Provision for labor contingencies

At June 30, 2005, the Company is party in various labor processes and the total amount being disputed in these processes amounts to R\$ 3,940 (R\$ 3,573 at March 31, 2005). The consolidated provision for labor contingencies totaling R\$ 2,798 at June 30, 2005 (2,718 at March 31, 2005) was recorded based on information in respect of the labor cases, provided by the legal advisors. The Company adopts the criteria of recording provisions for all cases with a probability of loss and in addition, adopts a more conservative posture, making provisions of 50% for the cases with a possible risk, in accordance with the classification of risk provided by the legal advisors.

c. Provision for civil contingencies

At June 30, 2005, the Company is party in various legal processes related to civil questions, and the total amount being disputed in these processes amounts to R\$ 4.878 (R\$ 4.264 at March 31, 2005). The consolidated provisions for civil contingencies totaling R\$ 1,803 at June 30, 2005 (R\$ 1,759 at March 31, 2005) refer basically to errors in diagnosis R\$ 1,231, problems with customer service R\$ 118 and others R\$ 454. The Company adopts the criteria of recording provisions for all cases with probable risk of loss and in addition, adopting a more conservative posture, records provisions of 50% for possible risk of loss, according to the classification of risk provided by the legal advisors.

d. Provision for tax contingencies

Provisions for tax contingencies refer basically to the following:

	<u>Parent Company</u>		<u>Consolidated</u>	
	<u>June 30, 2005</u>	<u>March 31, 2005</u>	<u>June 30, 2005</u>	<u>March 31, 2005</u>
Taxes and dues - Municipality of São Paulo	620	598	620	598
COFINS - Increase in rate	-	-	2,121	2,123
INSS	-	-	60	100
Administrative proceedings - Federal Revenue Department	-	-	64	206
Lawyers' fees related to legal proceedings regarding tax	<u>-</u>	<u>-</u>	<u>748</u>	<u>748</u>
	<u>620</u>	<u>598</u>	<u>3,613</u>	<u>3,775</u>

19 Processes with legal deposits

	<u>Parent Company</u>		<u>Consolidated</u>	
	<u>June 30, 2005</u>	<u>March 31, 2005</u>	<u>June 30, 2005</u>	<u>March 31, 2005</u>
INSS - process 1993 to 1999 (a)	1,504	-	1,504	-
Labor	35	35	127	127
Tax	2,813	2,816	3,442	2,816
Civil	<u>12</u>	<u>12</u>	<u>12</u>	<u>12</u>
	<u>4,364</u>	<u>2,863</u>	<u>5,085</u>	<u>2,955</u>

a. INSS Independent Professionals - 1993 to 1999

Refers to the Tax Notification for Debt Entry - NFLD number 35.109.011-8 of December 16, 1999, National Institute for Social Security - INSS, charging for Social Security contributions supposedly due on remuneration paid to doctors, independent professionals, providing services to Bio-Ciência Lavoisier Análises Clínicas S.A., as a result of these doctors not considered to be independent professionals, based on the reasons presented by the INSS tax authorities, with respect to the period August 1993 to September 1999, the period prior to this company being purchased by the Company. The Company has recorded a provision for the amounts involved, plus the fine and interest, based on the opinion of its legal advisors, who consider the chances of a successful outcome to be possible. On May 04, 2005, an annulment action for the tax debt was proposed, and on May 10, a petition was presented, with the supporting documentation of the legal deposits made on May 05, and 10, which amount to R\$ 1.901. In the quarterly information at March 31, 2005, this contingency was registered under the heading INSS - Process 1993 to 1999, for the amount of R\$ 1.504, together with other processes of the same nature. This process was reclassified at June 30, 2005, to the heading processes with legal deposits.

At June 30, 2005, the Company was a party to various tax and administrative legal proceedings. The most significant of these proceedings are:

Deductibility of amounts registered as goodwill and other operational costs and expenses (Process 10882.001031/2004-95)

The Federal Internal Revenue office at Osasco/SP filed an assessment on May 27, 2004, disallowing a significant amount of the amortization of goodwill arising from the purchase of subsidiaries in 1999. At June 30, 2005, the corrected value is approximately R\$ 43,900, and in the opinion of our legal advisors, the chances of an unfavorable outcome are remote.

ICMS tax on imports (before Constitutional Amendment 33/01)

The Company believes that it was not obliged to pay ICMS, a state value-added tax, on imports of materials and equipment because it was not a taxpayer covered by the applicable law. The Company has filed a lawsuit for each import before Constitutional Amendment 33/01, and the state of São Paulo has initiated an administrative proceeding such that, at June 30, 2005, 133 legal proceedings were pending regarding this issue. At June 30, 2005, the total amount in question was approximately R\$ 9,700 but the company has not recorded provisions for these proceedings. Based on the advice of their external legal counsel, the chances of losing these proceedings are remote and, therefore, the company has not recorded provisions for these amounts.

ISSQN - Service tax

In 2001, the City of São Paulo tax authorities initiated administrative proceedings seeking payment of the ISS tax, a municipal tax on services, on certain clinical tests. The tax authorities asserted that the clinical tests are rendered in the municipalities where they collect blood and other samples for clinical tests and that the ISS tax is due on that service. The Company has consistently paid the ISS on their performance of clinical tests to the municipality of Barueri, where their Alphaville central laboratory is located and where their clinical tests effectively occur. There are 212 administrative proceedings pending on this matter since the tax is payable monthly and several separate proceedings are opened each month. At June 30, 2005, the total amount in question was approximately R\$ 26,800, but the Company has not recorded provisions for these proceedings. Based on the advice of their external legal counsel, it believes the chances of losing these proceedings are remote. Additionally, there is a proceeding pending against Elkis e Furlanetto in which the ISS charged by the municipality of Santo André is being challenged. At June 30, 2005, the total amount under discussion was R\$ 6,200 and, based on the advice of external counsel the chance of the companies receiving an unfavorable decision in these proceedings and processes is remote.

Approximately R\$ 17,800 in tax proceedings claimed against the Company relate to companies that have been acquired. The amounts claimed in those proceedings refer to events incurred whilst these companies were controlled by the previous shareholders. Future payments are due on the purchase of these companies, payable to the previous owners, which could be reduced to compensate these tax liabilities.

20 Shareholders' equity

a. Capital social

As at June 30, 2005, total capital and paid in capital amounted to R\$ 216,136, represented by 53,607,935 ordinary shares with no par value.

b. Special reserve for goodwill on merger

The goodwill originating from the merger of the parent companies, classified under capital reserves accounts, has an amortization period of 5 years and as at June 30, 2005 consisted of the following:

Consolidated						
		Amortization rate % p.a.	June 30, 2005			March 31, 2005
End of amortization	Cost		Amortization	Residual	Residual	
Platypus Holdings Ltda	Feb/2006	20	<u>50,023</u>	<u>(42,953)</u>	<u>7,070</u>	<u>9,959</u>

c. Dividends

The statutes guarantee the shareholders the right to receive a minimum dividend of 25% of the net profit for the year, adjusted in accordance with Article 202 of Law 6.404/76.

21 Income tax and social contribution

	Income tax		Social contribution	
	Parent Company		Parent Company	
	June 30, 2005	March 31, 2005	June 30, 2005	March 31, 2005
Income before income tax	16,252	8,595	16,252	8,595
Adjustments to the profit				
Permanent additions	2,459	1,593	2,459	1,593
Temporary additions	<u>5,216</u>	<u>2,496</u>	<u>5,216</u>	<u>2,496</u>
Taxable profit before compensation of tax loss	23,927	12,684	23,927	12,684
Compensation of tax loss (30%)	<u>(7,178)</u>	<u>(3,805)</u>	<u>(7,178)</u>	<u>(3,805)</u>
Taxable income for the period	<u>16,749</u>	<u>8,879</u>	<u>16,749</u>	<u>8,879</u>
Income tax expense for the period	4,175	2,214	1,507	799
Effective rate	25%	25%	9%	9%

22 Tax loss carry-forwards

At June 30, 2005, the Company had the following tax loss carry-forwards:

a. Income tax losses	27,642
b. Negative social contribution base	31,159

Compensation of the tax losses for income tax and the negative social contribution base is limited to 30% of annual taxable profits, with no limitation period.

23 Financial instruments

The Company has a policy of reducing market risks, avoiding positions which may be exposed to fluctuations in market values and operating only with derivative financial instruments which permit control over risks. The major part of contracts involving derivatives is with swap transactions involving pre-fixed rates. The Company does not expect to incur any losses with these transactions beyond those already recorded in the consolidated financial statements.

The market values were estimated at the balance sheet date based on relevant market information. Changes in the assumptions may significantly affect the estimates presented.

The management of these instruments is implemented through operating strategies, aimed at liquidity, profitability and security. The control policy consists of permanent follow-up of the rates engaged versus those in force in the market. The Company does not invest in derivatives or any other risk assets on a speculative basis.

a. Composition of balances

In compliance with CVM Instruction 235/95, the accounting balances and the market values of the financial instruments included in the consolidated balance sheet at June 30, 2005 are presented below:

Description	Accounting		Market value	
	Parent company	Consolidated	Parent company	Consolidated
Cash and cash equivalents	3,467	3,793	3,467	3,793
Marketable securities	137,839	137,842	137,839	137,842
Taxes recoverable	19,113	20,602	19,113	20,602
Related parties	13,101	-	13,101	-
Advances for future capital increase	6,218	-	6,218	-
Investments valued using the equity method	<u>8,180</u>	<u>30,808</u>	<u>8,180</u>	<u>30,808</u>

Description	Accounting		Market value	
	Parent company	Consolidated	Parent company	Consolidated
Assets	<u>187,918</u>	<u>193,045</u>	<u>187,918</u>	<u>193,045</u>
Loans and financing				
In local currency	49,038	50,161	49,038	50,161
In foreign currency	56,271	56,271	50,076	50,076
Swap	<u>24,824</u>	<u>24,824</u>	<u>20,989</u>	<u>20,989</u>
Liabilities	<u>130,133</u>	<u>131,256</u>	<u>120,103</u>	<u>121,226</u>

b. Criteria, premises and limitations used to calculate the market value

Cash and cash equivalents and interest earnings bank deposits

Current accounts held with banks have market values identical to the book values.

For interest earnings bank deposits, the market value was calculated based on the market quotations of these securities.

Taxes recoverable

Taxes recoverable are presented at book values, since there is no information to determine their market value.

Related parties and advances for future capital increases

Presented at book values, since there are no similar instruments on the market and they refer to operations with related parties.

Investments

The market values for interests in companies were calculated based on the book value. The market values for other investments are identical to the book values, since they have no market quotations.

Loans and financing

The market values of loans and financing were calculated based on their present value calculated based on the future cash flows and using interest rates applicable to instruments of a similar nature, with similar terms and risks, or based on the market quotations of these securities.

Derivatives

The Company operates only with derivative instruments, not for speculative purposes, aimed to protect against foreign exchange variations.

Limitations

The market values were estimated at the balance sheet date, based on “relevant market information”. Changes in the assumptions may significantly affect the estimates presented.

c. Exchange rate risk

The Company’s results and those of its subsidiaries are subject to significant variations, as their liabilities are linked to exchange rate fluctuations, especially the US dollar.

As a strategy to prevent and reduce the effects from foreign exchange fluctuations, foreign currency bank borrowings are fully protected by means of swap operations with financial institutions, and the foreign currency debts with suppliers of equipment are also protected, for the sum of R\$ 25,322, also be means of swap operations with financial institution. No operations were contracted to protect against foreign exchange risks for debts with suppliers.

	<u>Parent Company</u>		<u>Consolidated</u>	
Liabilities	June 30, 2005	March 31, 2005	June 30, 2005	March 31, 2005
Bank Loans	26,496	29,812	26,496	29,812
Equipment suppliers	54,599	54,941	54,599	54,941
Suppliers	<u>3,212</u>	<u>3,301</u>	<u>3,212</u>	<u>3,301</u>
	<u>84,307</u>	<u>88,054</u>	<u>84,307</u>	<u>88,054</u>

24 Insurance coverage (not reviewed)

The Company had insurance taken out with the major insurance companies in Brazil, which were determined in accordance with the advice from experts, and considering the nature and the level of risk involved. The main insurance coverage is against fire, theft, loss of profit and various risks for the fixed assets and inventories, at values considered sufficient to cover possible losses.

25 Leasing transactions

National Leasing

The Company has leasing arrangements for machines and equipment and data processing equipment (hardware) with a purchase option, based on 18 leasing contracts in force as of June 30, 2005. The average term of the contracts is 36 months at rates varying from CDI + 1.59 % p.a. to CDI + 3,20 % p.a.

Rental expense recorded for the period ended June 30, 2005 amounted to R\$ 1,302 (R\$ 396 at June 30, 2004).

The position of the amounts payable arising from lease contracts by year of disbursement is as follows:

	<u>Parent Company</u>
	June 30, 2005
2005	1,204
2006	2,108
2007	1,073
2008	<u>88</u>
	<u>4,473</u>

International Leasing

The Company is the lease for equipment used to provide services with the option to purchase, according to the lease contract effective as from February 28, 2005, valid for a period of 84 months, with a grace period of six months for paying the first installment, fixed in North American dollars, with the dollar valued at market on the payment date for each quarterly installment, plus interest of 7.85% p.a..

The position for amounts payable arising from leasing contracts at June 30, 2005, is US\$ 1.000 thousand, with payments due until 2012.

26 Guarantees and sureties

The Company granted sureties to its subsidiary Elkis e Furlanetto C.D.A.C. Ltda., with Banco Safra S.A. and Banco Bradesco S.A. for the sum of R\$ 4,500.

27 Subsequent events

a. Purchase

On July 05, 2005, the Company purchased 21,371,573 ordinary nominal shares in Laboratório Frischmann Aisengart S.A., representing 92.92% of the 23,000,000 shares which comprise its capital. The purchase price amounted to R\$ 30,000, paid from the Company's own resources, being R\$ 27,000 attributed to clinical analyses activities and R\$ 3,000 attributed to image examinations, environmental analyses, analyses of genetically modified organisms and toxicological analyses, representing an opportunity for the Company to enter new market segments.

The remaining capital is held by Sr. James Frischmann Aisengart, a minority shareholder with an interest of 7.08% in the capital, equivalent to 1,628,427 ordinary shares. He does not hold a management position and is in litigation with Laboratório Frischmann Aisengart S.A. and its previous shareholders.

b. Incorporation

According to the protocol for the justification of incorporation dated July 14, 2005, the Company decided to incorporate the companies Centro Radiológico da Lagoa Ltda., Presmedi Rio Serviços Médicos Ltda., Elkis e Furlanetto Centro de Diagnósticos e Análises Clínicas Ltda., Elkis e Furlanetto Laboratório Médico Ltda. and Laboratório Pasteur Patologia Clínica S/S Ltda.. On July 15, 2005, the market was informed of this matter through publication of a relevant fact, which will be considered by the Company in General Meeting, summoned for August 01, 2005.

28 Cashflow statements - indirect method [optional supplementary information]

The company has presented the statement of cashflow as supplementary information, prepared in accordance with NPC 20 - Statement of Cashflow, issued by IBRACON -Institute of Independent auditors in Brazil.

	Parent Company		Consolidated	
	6/30/05	6/30/04	6/30/05	6/30/04
Six-months period ended June 30, 2005 and 2004				
Cashflow from operational activities				
Net income for the period	4.988	(7.954)	4.988	(7.954)
Adjustments to reconcile the results to the cash generated from operational results				
Depreciation and amortization	9.512	7.240	9.918	7.546
Amortization of goodwill on investments	1.936	911	1.936	911
Amortization of goodwill on deferred	3.269	4.947	3.269	4.947
Amortization of goodwill on shareholders' equity	2.889	5.832	2.889	5.832
Results from writing off permanent assets	(197)	(6)	262	(6)
Equity in net income of subsidiaries	749	621	-	-
Changes in assets and liabilities				
(Increase) in trade accounts receivable	(1.025)	(3.027)	(1.350)	(8.532)
Decrease (increase) in inventories	992	(587)	992	(809)
(Increase) decrease in recoverable taxes	(1.137)	991	(1.230)	120
(Increase) in other accounts receivable	(2.799)	(3.300)	(3.429)	(5.916)
(Increase) in current accounts with related parties	(4.715)	(6.291)	-	(53)
Decrease in credits with previous owners	-	-	1.084	-
(Increase) decrease in advances to suppliers	(434)	(667)	(435)	(606)
Decrease in prepayments	623	221	615	54
(Increase) in suppliers	497	2.439	715	4.419
Increase in salaries, social security charges and vacation payable	3.646	2.940	4.750	7.693
(Decrease) increase in installment taxes	(190)	(122)	(1.607)	4.249
Increase (decrease) in taxes and contributions payable	2.632	(1.491)	2.650	2.403
(Decrease) in goods and rights from previous management	-	-	(1.084)	-
Increase in accounts payable to related parties	-	20.000	-	20.000
(Decrease) increase in accounts payable from acquisition of subsidiary	(2.278)	8.235	(2.279)	8.235
Increase in provision for contingencies	1.831	(2.464)	2.316	17
Increase in accounts payable	3.269	569	3.439	517
Net bank and cash generated from operational activities	24.058	29.037	28.409	43.067
Cashflow from investment activities				
(Increase) from fixed asset purchases	(15.643)	(12.850)	(15.643)	(12.850)
(Increase) in permanent assets from purchase of companies	-	-	(1.673)	(4.183)
Decrease from purchase of investment interests	1.883	-	-	-
(Increase) in goodwill on purchase of investments	(7.883)	(6.977)	(7.883)	(18.114)
(Increase) in deferred charges	(943)	(3.865)	(943)	(3.865)
Net bank and cash applied in investment activities	(22.586)	(23.692)	(26.142)	(39.012)
Cashflow from financing activities				
Capital reduction	-	(20.000)	-	(20.000)
(Decrease) increase in borrowings and financing	(972)	11.436	(1.671)	13.063
Net bank and cash (invested) generated from financing activities	(972)	(8.564)	(1.671)	(6.937)
Increase in bank and cash equivalents	500	(3.219)	596	(2.882)
Bank and cash equivalents at start of period	131.192	29.511	131.425	29.560
Bank and cash equivalents at end of period	131.692	26.292	132.021	26.678

29 EBITDA

Six-month period ended as of June 30, 2005	Parent Company		Consolidated	
	2005	2004	2005	2004
Operational results	16,541	(4,802)	16,663	(5,695)
Adjustments:				
Depreciation and amortization (costs)	16,649	12,531	16,649	12,531
Depreciation and amortization (general and admin.)	1,915	1,211	2,654	1,654
Net financial expenses	5,834	12,472	7,750	13,572
Equity in income of subsidiaries	2,235	1,128	-	-
Amortization of goodwill	<u>15,845</u>	<u>22,914</u>	<u>15,845</u>	<u>22,914</u>
EBITDA	<u>59,019</u>	<u>45,454</u>	<u>59,561</u>	<u>44,976</u>
Quarter ended as of June 30, 2005	Parent Company		Consolidated	
	2005	2004	2005	2004
Operational results	7,732	(6,122)	7,859	(7,340)
Adjustments:				
Depreciation and amortization (costs)	8,590	6,551	8,590	6,551
Depreciation and amortization (general and admin.)	922	632	1,329	938
Net financial expenses	2,493	6,523	3,089	7,460
Equity in income of subsidiaries	749	621	-	-
Amortization of goodwill	<u>8,095</u>	<u>11,691</u>	<u>8,095</u>	<u>11,691</u>
EBITDA	<u>28,581</u>	<u>19,896</u>	<u>28,962</u>	<u>19,300</u>

30 Shareholding at June 30, 2005

Quarterly information at June 30, 2005 - Other material information

Shareholding

The shareholding of the shareholders with more than 5% of shares with voting rights at June 30, 2005.

Name/Corporate name	Nationality	Common shares	%	Total shares	%
DASA Participações S.A.	Brazilian	30,745,723	57.35	30,745,723	57.35
Other shareholders	-	978,127	1.82	978,127	1.82
Outstanding shares in the market	-	<u>21,884,087</u>	<u>40.82</u>	<u>21,884,087</u>	<u>40.82</u>
Total		<u>53,607,935</u>	<u>100.00</u>	<u>53,607,935</u>	<u>100.00</u>

Distribution of the capital of the controlling company DASA Participações S.A. at June 30, 2005.

Name/Corporate name	Nationality	Common shares	%	Preferred shares	%	Total shares	%
Balu 460 Participações S.A.	Brazilian	28,519,986	51.00	-	0.00	28,519,986	36.96
Platypus S.A.	Brazilian	27,401,562	49.00	21,250,140	100.00	48,651,702	63.04
Caio Roberto Chimenti Auriemo	Brazilian	1	0.00	-	0.00	1	0.00
Other shareholders	-	<u>8</u>	<u>0.00</u>	<u>-</u>	<u>0.00</u>	<u>8</u>	<u>0.00</u>
Total		<u>55,921,557</u>	<u>100.00</u>	<u>21,250,140</u>	<u>100.00</u>	<u>77,171,697</u>	<u>100.00</u>

Distribution of the capital of the controlling company Balu 460 Participações S.A. at June 30, 2005.

Name/Corporate name	Nationality	Common shares	%	Total shares	%
Caio Roberto Chimenti Auriemo	Brazilian	1,748,594	100.00	1,748,594	100.00
Other shareholders	-	<u>1</u>	<u>0.00</u>	<u>1</u>	<u>0.00</u>
Total		<u>1,748,595</u>	<u>100.00</u>	<u>1,748,595</u>	<u>100.00</u>

Distribution of the capital of the controlling company Platypus S.A. at June 30, 2005.

Name/Corporate name	Nationality	Common shares	%	Preferred shares	%	Total shares	%
Patrimônio Brasil Private Equity FMIA-CL	Brazilian	12,868,919	31.32	-	0.00	12,868,919	10.44
Brazilian Analysis and Diag. Private Inv LLP	United Kingdom	11,248,270	27.38	41,608,989	50.65	52,857,259	42.89
Latin Healthcare Fund LP	United States	3,637,303	8.85	10,643,037	12.95	14,280,340	11.59
PP Participações S.A.	Brazilian	3,174,277	7.73	-	0.00	3,174,277	2.58
OPCO Brazil Private Equity LLC	Cayman Islands	2,782,382	6.77	1,147,820	1.40	3,930,202	3.19
Other shareholders	-	<u>7,378,289</u>	<u>17.96</u>	<u>28,754,335</u>	<u>35.00</u>	<u>36,132,624</u>	<u>29.32</u>
Total		<u>41,089,440</u>	<u>100.00</u>	<u>82,154,181</u>	<u>100.00</u>	<u>123,243,621</u>	<u>100.00</u>

Distribution of the capital of the controlling company PP Participações S.A. at June 30, 2005.

Name/Corporate name	Nationality	Common shares	%	Total shares	%
JRS Empreendimentos e Participações Ltda.	Brazilian	63,524	28.87	63,524	28.87
GB & Associados Adm. Consultoria Ltda.	Brazilian	55,490	25.22	55,490	25.22
Carol Administração Consult. Ltda.	Brazilian	54,283	24.67	54,283	24.67
Lorema Administração Consult. Ltda.	Brazilian	16,281	7.40	16,281	7.40
Asaigh Administração Consult. Ltda.	Brazilian	11,039	5.02	11,039	5.02
Dominion Capital Participações Ltda.	Brazilian	11,000	5.00	11,000	5.00
Other shareholders	-	<u>8,383</u>	<u>3.81</u>	<u>8,383</u>	<u>3.81</u>
		<u>220,000</u>	<u>100.00</u>	<u>220,000</u>	<u>100.00</u>

Distribution of the capital of the controlling company JRS Empreendimentos e Participações Ltda. at June 30, 2005.

Name/Corporate name	Nationality	Quotas	%	Total shares	%
Jair Ribeiro Silva Neto	Brazilian	2,269,402	99.97	2,269,402	99.97
Other shareholders	-	<u>598</u>	<u>0.03</u>	<u>598</u>	<u>0.03</u>
Total		<u>2,270,000</u>	<u>100.00</u>	<u>2,270,000</u>	<u>100.00</u>

Distribution of the capital of GB & Associados Adm.Consultoria Ltda. at June 30, 2005.

Name/Corporate name	Nationality	Quotas	%	Total shares	%
Giampaolo Maria Sisto Felice Baglioni	Brazilian	1,875,090	99.99	1,875,090	99.99
Other shareholders	-	<u>210</u>	<u>0.01</u>	<u>210</u>	<u>0.01</u>
Total		<u>1,875,300</u>	<u>100.00</u>	<u>1,875,300</u>	<u>100.00</u>

Distribution of the capital of the controlling company Carol Administração Consult. Ltda. at June 30, 2005.

Name/Corporate name	Nationality	Quotas	%	Total shares	%
Olimpio Matarazzo Neto	Brazilian	1,498,899	99.99	1,498,899	99.99
Other shareholders	-	<u>201</u>	<u>0.01</u>	<u>201</u>	<u>0.01</u>
Total		<u>1,499,100</u>	<u>100.00</u>	<u>1,499,100</u>	<u>100.00</u>

Distribution of the capital of the controlling company Lorema Administração Consult. Ltda. at June 30, 2005.

Name/Corporate name	Nationality	Quotas	%	Total shares	%
Luiz Otavio Reis de Magalhães	Brazilian	584,526	99.92	584,526	99.92
Other shareholders	-	<u>474</u>	<u>0.08</u>	<u>474</u>	<u>0.08</u>
Total		<u>585,000</u>	<u>100.00</u>	<u>585,000</u>	<u>100.00</u>

Distribution of the capital of the controlling company Asaigh Administração e Consult. Ltda. at June 30, 2005.

Name/Corporate name	Nationality	Quotas	%	Total shares	%
Round Mountain International Ltd.	British Virgin	4,861,406	97.97	4,861,406	97.97
Alexandre Teixeira de Assumpção Saigh	Brazilian	100,469	2.03	100,469	2.03
Other shareholders	-	<u>90</u>	<u>0.00</u>	<u>90</u>	<u>0.00</u>
Total		<u>4,961,965</u>	<u>100.00</u>	<u>4,961,965</u>	<u>100.00</u>

Distribution of the capital of the controlling company Dominion Capital Participações Ltda. at June 30, 2005.

Name/Corporate name	Nationality	Quotas	%	Total shares	%
Luiz Chrysostomo de Oliveira Filho	Brazilian	162,800	99.88	162,800	99.88
Other shareholders	-	<u>200</u>	<u>0.12</u>	<u>200</u>	<u>0.12</u>
Total		<u>163,000</u>	<u>100.00</u>	<u>163,000</u>	<u>100.00</u>

Shareholding at June 30, 2005

Controllers and Administrators

	Common shares	%	Total shares	%
Shareholders:				
Controllers	31,723,842	59.18	31,723,842	59.18
Members of the board of directors	<u>6</u>	<u>0.00</u>	<u>6</u>	<u>0.00</u>
Total	31,938,734	59.18	31,938,734	59.18
Outstanding shares	<u>21,884,087</u>	<u>40.42</u>	<u>21,884,087</u>	<u>40.42</u>
Total shares	<u>53,607,935</u>	<u>100.00</u>	<u>53,607,935</u>	<u>100.00</u>